Published in Blood on November 04, 2011
Non-coding RNAs as direct and indirect modulators of epigenetic regulation. Epigenetics (2014) 1.09
Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB. PLoS Genet (2013) 1.08
Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma. Oncogene (2012) 1.03
Independent genomewide screens identify the tumor suppressor VTRNA2-1 as a human epiallele responsive to periconceptional environment. Genome Biol (2015) 0.99
Epigenetic silencing of the non-coding RNA nc886 provokes oncogenes during human esophageal tumorigenesis. Oncotarget (2014) 0.94
Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing. Sci Rep (2013) 0.94
Comparative anatomy of chromosomal domains with imprinted and non-imprinted allele-specific DNA methylation. PLoS Genet (2013) 0.93
nc886, a non-coding RNA of anti-proliferative role, is suppressed by CpG DNA methylation in human gastric cancer. Oncotarget (2014) 0.92
DNA methylation patterns in naïve CD4+ T cells identify epigenetic susceptibility loci for malar rash and discoid rash in systemic lupus erythematosus. Lupus Sci Med (2015) 0.91
A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy. PLoS One (2014) 0.88
Variable maternal methylation overlapping the nc886/vtRNA2-1 locus is locked between hypermethylated repeats and is frequently altered in cancer. Epigenetics (2014) 0.87
A tumor surveillance model: a non-coding RNA senses neoplastic cells and its protein partner signals cell death. Int J Mol Sci (2012) 0.87
Long non-coding RNAs in haematological malignancies. Int J Mol Sci (2013) 0.83
Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome. Oncotarget (2015) 0.82
Reprogramming of the human intestinal epigenome by surgical tissue transposition. Genome Res (2014) 0.80
A Novel Type of Non-coding RNA, nc886, Implicated in Tumor Sensing and Suppression. Genomics Inform (2015) 0.78
Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients. Genes (Basel) (2015) 0.76
Tissue-specific patterns of allelically-skewed DNA methylation. Epigenetics (2016) 0.76
nc886, a non-coding RNA and suppressor of PKR, exerts an oncogenic function in thyroid cancer. Oncotarget (2016) 0.75
Regulation of p53 expression and apoptosis by vault RNA2-1-5p in cervical cancer cells. Oncotarget (2015) 0.75
Human non-coding RNA 886 (nc886) adopts two structurally distinct conformers that are functionally opposing regulators of PKR. RNA (2017) 0.75
Nucleosome Positioning and NDR Structure at RNA Polymerase III Promoters. Sci Rep (2017) 0.75
Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs. Int J Mol Sci (2016) 0.75
Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference? Cancers (Basel) (2017) 0.75
A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A (1992) 29.51
MicroRNA genes are transcribed by RNA polymerase II. EMBO J (2004) 20.65
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science (2010) 9.78
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol (2011) 6.48
Ribosomopathies: human disorders of ribosome dysfunction. Blood (2010) 4.43
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2010) 4.12
Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med (2009) 4.03
Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood (2001) 3.90
The dsRNA protein kinase PKR: virus and cell control. Biochimie (2007) 3.67
Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell (2007) 3.59
Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A (2002) 3.50
Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood (2002) 2.50
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood (2010) 2.40
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A (2007) 2.39
Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood (2007) 2.30
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med (2006) 2.23
Telomere maintenance and human bone marrow failure. Blood (2008) 2.09
Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome. Genes Dev (2011) 1.89
Non-imprinted allele-specific DNA methylation on human autosomes. Genome Biol (2009) 1.64
Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res (2008) 1.57
Defining the RNA polymerase III transcriptome: Genome-wide localization of the RNA polymerase III transcription machinery in human cells. Genome Res (2010) 1.57
HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood (1988) 1.51
Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood (2009) 1.50
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (2010) 1.48
The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs. Nat Cell Biol (2009) 1.48
RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res (2007) 1.48
Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell Mol Life Sci (2009) 1.39
Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity. RNA (2011) 1.32
Evolution of vault RNAs. Mol Biol Evol (2009) 1.31
Allele-specific methylation of the human c-Ha-ras-1 gene. Cell (1987) 1.31
Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood (2000) 1.26
The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res (2010) 1.25
Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood (2010) 1.21
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica (2011) 1.15
Profiling DNA methylation by melting analysis. Methods (2002) 1.12
Epstein-barr virus-induced expression of a novel human vault RNA. J Mol Biol (2009) 1.12
MiR-886-3p down regulates CXCL12 (SDF1) expression in human marrow stromal cells. PLoS One (2010) 1.09
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res (2009) 1.09
Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS One (2010) 1.07
MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecol Oncol (2010) 1.04
Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress. Leukemia (2010) 0.92
Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther (2009) 0.91
Human mortalin (HSPA9): a candidate for the myeloid leukemia tumor suppressor gene on 5q31. Leukemia (2000) 0.90
Evaluation of ETF1/eRF1, mapping to 5q31, as a candidate myeloid tumor suppressor gene. Cancer Genet Cytogenet (2002) 0.88
A role for PKR in hematologic malignancies. J Cell Physiol (2010) 0.87
PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. J Cell Physiol (2009) 0.83
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A (2002) 12.33
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Epigenetics in cancer. Carcinogenesis (2009) 7.49
The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev (2007) 6.77
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2009) 6.54
Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov (2006) 6.39
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol (2012) 5.52
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood (2008) 4.66
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43
Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med (2008) 4.41
Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci U S A (2004) 4.39
Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A (2008) 4.20
Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol (2006) 4.13
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2010) 4.12
Rethinking how DNA methylation patterns are maintained. Nat Rev Genet (2009) 4.03
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood (2002) 3.89
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol (2002) 3.61
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
The CpG island searcher: a new WWW resource. In Silico Biol (2003) 3.42
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell (2007) 3.15
DNA methylation and breast carcinogenesis. Oncogene (2002) 3.03
Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res (2002) 3.02
DNA methylation: the nuts and bolts of repression. J Cell Physiol (2007) 3.00
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood (2011) 2.96
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol (2011) 2.88
Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell (2008) 2.87
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res (2009) 2.83
Crystal structure of the specificity domain of ribonuclease P. Nature (2003) 2.69
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69
Epigenetics and microRNAs. Pediatr Res (2007) 2.52
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell (2008) 2.46
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A (2007) 2.39
Preferential response of cancer cells to zebularine. Cancer Cell (2004) 2.39
Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol (2009) 2.34
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A (2006) 2.25
Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst (2003) 2.22
Towards a joint definition of European hematology. Haematologica (2012) 2.17
Polycomb-repressed genes have permissive enhancers that initiate reprogramming. Cell (2011) 2.14
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med (2010) 2.11
Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) (2008) 2.04
Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle (2006) 1.98
Epigenetic changes in cancer. APMIS (2007) 1.96
Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res (2012) 1.95
Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res (2005) 1.94
Structure and function of plant photoreceptors. Annu Rev Plant Biol (2010) 1.93
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol (2008) 1.90
H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes. Mol Cell (2010) 1.85
Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol Cancer Ther (2005) 1.85
DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet (2011) 1.83
Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol (2008) 1.83
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood (2009) 1.80
DNA methylation and cellular reprogramming. Trends Cell Biol (2010) 1.77
Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun (2008) 1.74
Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med (2009) 1.73
Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res (2002) 1.71
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res (2004) 1.68
Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol (2004) 1.68
Automated crystallographic system for high-throughput protein structure determination. Acta Crystallogr D Biol Crystallogr (2003) 1.67
CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Eur J Haematol (2006) 1.66
MicroRNAs and cancer. APMIS (2007) 1.66
Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res (2007) 1.65
Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer (2009) 1.64